Eczema and psoriasis are both chronic inflammatory skin conditions that cause red, itchy patches, but they differ in how they look, where they appear, what drives them, and how they’re treated. The confusion is understandable: both can flare and fade, both run in families, and both disrupt daily life. But the distinctions matter because they lead to different treatments and different health risks down the road.
Where They Show Up on the Body
One of the quickest ways to tell these conditions apart is location. Eczema favors the flexural areas of your body, the spots where skin folds inward: the inner creases of your elbows, behind your knees, your wrists, neck, and ankles. It’s also more common on the face and neck than psoriasis is. If you picture the soft, inner side of a joint, that’s eczema territory.
Psoriasis does the opposite. It tends to show up on the extensor surfaces, the outer edges of your elbows and knees where skin stretches over bone. Beyond those classic spots, psoriasis commonly affects the scalp, lower back, palms, soles of the feet, ears, and nails. It can also develop in skin folds like the groin or genital region, which is sometimes called inverse psoriasis and can add to the confusion with eczema.
How the Patches Look and Feel
The visual differences are often subtle but consistent. Eczema typically appears as dry, rough patches without sharp edges. The skin may look inflamed and weepy during a flare, then dry and leathery between flares from repeated scratching (a process called lichenification). Psoriasis produces thicker, more raised plaques with sharply defined borders and silvery-white scales that build up on the surface. If you ran your finger along the edge of a psoriasis plaque, you’d feel a distinct step where the raised skin meets normal skin. Eczema patches tend to blend more gradually into the surrounding area.
Both conditions itch, but the sensation differs. Eczema is defined by intense, sometimes relentless itching that drives scratching, which in turn worsens the rash. It’s a vicious cycle that can disrupt sleep and concentration. Psoriasis can itch too, but people with psoriasis more commonly describe soreness, stinging, or pain, especially when plaques crack. Joint pain is another complaint unique to psoriasis, a signal that the condition may be affecting more than just the skin.
What’s Happening Under the Skin
Both conditions involve an overactive immune system, but they’re driven by different branches of your immune response. Eczema (formally called atopic dermatitis) is primarily a Th2-driven disease. The immune signaling molecules IL-4 and IL-13 are the main forces behind the inflamed, hyperproliferative skin you see in an eczema flare. Another molecule, IL-22, plays a particularly important role in the acute phase of eczema, worsening the hallmark features: spongiosis (fluid buildup between skin cells), defects in how new skin cells mature, and breakdown of the skin barrier.
Psoriasis runs on a different track. It’s driven mainly by Th17 cells and the cytokine IL-17, which push skin cells to reproduce far too quickly. Normal skin cells take about a month to mature and shed. In psoriasis, that process compresses to just a few days, causing cells to pile up on the surface and form those characteristic thick, scaly plaques.
This distinction isn’t just academic. It’s why the two conditions respond to different medications. A drug that blocks IL-4 and IL-13 can dramatically improve eczema but won’t help psoriasis, and vice versa for drugs targeting IL-17.
Who Gets Each Condition and When
Eczema is far more common in childhood. It affects roughly 10% to 20% of children worldwide and 2% to 10% of adults. Many children with eczema see their symptoms improve or resolve by adolescence, though it can persist into adulthood or reappear later in life. Psoriasis affects about 2% to 3% of the global population and more commonly appears in late adolescence or adulthood, though it can develop at any age.
Both conditions have a genetic component, but the family patterns differ. Eczema clusters with other allergic conditions: asthma, hay fever, and food allergies. This progression from eczema in infancy to respiratory allergies later in childhood is called the atopic march. Psoriasis, by contrast, is linked to a different set of associated conditions. About 30% of people with psoriasis eventually develop psoriatic arthritis, which causes joint swelling, stiffness, and pain. Psoriasis also carries higher rates of cardiovascular disease, metabolic syndrome, and depression.
What Triggers Flares
Eczema flares are often set off by environmental irritants and allergens: harsh soaps, fragrances, dust mites, pet dander, pollen, dry air, and sweat. Stress and temperature changes are common triggers too. The underlying barrier dysfunction in eczema skin means irritants that wouldn’t bother most people can provoke a flare.
Psoriasis shares some triggers with eczema (stress and dry winter air, for example) but has a distinctive one: the Koebner phenomenon. When someone with psoriasis injures their skin, even in a minor way, new psoriasis plaques can develop at the exact site of injury. Cuts, scratches, sunburns, insect bites, tattoos, even injections can set this off. The new lesions typically appear within 10 to 20 days, tend to run in a straight line following the shape of the wound, and look identical to the person’s existing psoriasis. This doesn’t happen in eczema.
Certain medications, infections (particularly strep throat), and heavy alcohol use can also trigger or worsen psoriasis flares in ways that don’t apply to eczema.
How Treatment Differs
First-line treatment for both conditions involves moisturizers and topical anti-inflammatory creams. But beyond those basics, the paths diverge.
For eczema, the priority is restoring the skin barrier and calming the Th2-driven inflammation. Thick emollients applied immediately after bathing are a cornerstone. When topical treatments aren’t enough, newer biologic therapies target the specific immune molecules (IL-4 and IL-13) that drive eczema. There are also oral medications that block the signaling pathways inside immune cells responsible for the inflammatory cascade.
Psoriasis treatment has a wider toolkit, partly because the condition has been a focus of biologic drug development for over two decades. The FDA has approved more than a dozen biologic therapies for psoriasis, targeting different points in the immune pathway: some block a broad inflammatory signal called TNF, others target IL-17 or IL-23 specifically. Phototherapy (controlled UV light exposure) is another established option for psoriasis that’s used less commonly for eczema. For people with psoriatic arthritis, treatment needs to address both skin and joints, and many of the same biologics approved for psoriasis also carry approval for joint disease.
Can You Have Both?
It’s uncommon but possible. Some people develop features of both conditions, and distinguishing between them can be genuinely difficult, even for dermatologists. When the diagnosis is unclear from a physical exam alone, a skin biopsy can help. Under a microscope, eczema shows spongiosis (fluid collecting between skin cells and causing a sponge-like appearance) along with irregular thickening of the outer skin layer. Psoriasis shows a more uniform thickening pattern, thinning of the granular layer, and characteristic small collections of immune cells trapped in the outermost layer of skin.
If you’re dealing with a persistent, itchy skin condition and aren’t sure which one it is, the location, appearance, and associated symptoms described above can help you have a more informed conversation with a dermatologist. Getting the right diagnosis matters because using psoriasis treatments for eczema, or vice versa, often means months of frustration with therapies that were never going to work.